View document text
23rd June, 2026
The Dy. General Manager (Listing Dept.) The Manager – Listing Dept.,
BSE Limited, National Stock Exchange of India Ltd.,
Corporate Relationship Dept., Exchange Plaza, 5th Floor,
1st Floor, New Trading Ring, Plot No. C/1, G. Block,
P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E),
Mumbai - 400 001 Mumbai – 400 051
(BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM)
Dear Sir,
Re: Proceedings of 53rd Annual General Meeting of the Company held on 23rd June, 2026
In terms of Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby inform you that
the following business was transacted at the 53rd Annual General Meeting (AGM) of the Company
held through Video Conferencing on 23rd June, 2026.
1. Approval and adoption of Standalone Financial Statements as at 31st March, 2026, including
the Audited Balance Sheet as at 31st March, 2026, the Statement of Profit and Loss for the year
ended on that date and reports of the Board of Directors and Auditors thereon.
2. Approval and adoption of Consolidated Financial Statements as at 31st March, 2026, including
the Audited Balance Sheet as at 31st March, 2026, the Statement of Profit and Loss for the year
ended on that date and reports of the Auditors thereon.
3. Confirmation of payment of interim dividend of ₹ 29.00 per equity share of fully paid up face
value of ₹ 5.00 each and declaration of final dividend of ₹ 9.00 per equity share of fully paid
up face value of ₹ 5.00 each for the financial year ended 31st March, 2026.
4. To appoint a Director in place of Samir Mehta (holding DIN: 00061903), Director, who retires
by rotation and being eligible, offers himself for re-appointment.
5. Ratification of remuneration of cost auditors of the Company for the year 2026-27.
6. Issuance of Equity Shares including Convertible Bonds / Debentures.
The above business were transacted by Remote e-voting and e-voting at the meeting as required
under Companies Act, 2013, Listing Regulations and Ministry of Corporate Affairs General
Email – investorservices@torrentpharma.com
circular no. 20 read with Circular nos. 14 & 17 of 2020 and 03 of 2025. Declaration of Results of
Voting along with Scrutinizer’s Report and Results of voting as required under Regulation 44(3)
of Listing Regulations will be disclosed to the Stock Exchanges separately.
The AGM commenced at 09:30 am and concluded at 10:05 am.
Kindy take note of the above.
Thanking you,
Yours Sincerely,
For TORRENT PHARMACEUTICALS LIMITED
CHINTAN M. TRIVEDI
COMPANY SECRETARY
Email – investorservices@torrentpharma.com